Evidence map›Paper›PMID 38381995›Full record

ArticleJCO oncology practice2024

Receipt of Guideline-Concordant Care Is Associated With Improved Survival in Patients With Osteosarcoma in California: A Population-Based Analysis.

Renata Abrahão, Theresa H M Keegan, Frances B Maguire, Qian Li, Marcio H Malogolowkin, Samantha Wong, Steven W Thorpe, Janai R Carr-Asher, Amanda M Midboe, R Lor Randall and 1 more

Open access · greenAbstract read
In one paragraph

Article in JCO oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Renata AbrahãoDivision of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis Comprehensive Cancer Center, Sacramento, CA.ORCID 0000-0002-1644-0313
Theresa H M KeeganDivision of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis Comprehensive Cancer Center, Sacramento, CA.ORCID 0000-0002-1961-4008
Frances B MaguireCalifornia Cancer Reporting and Epidemiologic Surveillance Program, University of California Davis Comprehensive Cancer Center, Sacramento, CA.ORCID 0000-0001-8490-6229
Qian LiDivision of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California Davis Comprehensive Cancer Center, Sacramento, CA.ORCID 0000-0002-8071-4016
Marcio H MalogolowkinDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA.
Samantha WongUniversity of California Davis School of Medicine, Sacramento, CA.
Steven W ThorpeDepartment of Orthopedic Surgery, University of California Davis School of Medicine, Sacramento, CA.
Janai R Carr-AsherDivision of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
Amanda M MidboeDivision of Public Health Science, University of California Davis School of Medicine, Sacramento, CA.
R Lor RandallDepartment of Orthopedic Surgery, University of California Davis School of Medicine, Sacramento, CA.ORCID 0000-0002-3660-774X
Elysia M AlvarezDivision of Pediatric Hematology/Oncology, Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA.ORCID 0000-0002-1071-1311
University of California, Davis · USUC Davis Comprehensive Cancer Center

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
NCCDPHP CDC HHS NU58DP006344NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032INCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

purposeTo examine the relationship between guideline-concordant care (GCC) on the basis of national clinical practice guidelines and survival in children (0-14 years), adolescents and young adults (AYAs, 15-39 years), and adults (40 years and older) with osteosarcoma, and to identify sociodemographic and clinical factors associated with receipt of GCC and survival.

methodsWe used data from the California Cancer Registry (CCR) on patients diagnosed with osteosarcoma during 2004-2019, with detailed treatment information extracted from the CCR text fields, including chemotherapy regimens. Multivariable logistic and Cox proportional hazard regression were used for statistical analyses.

resultsOf 1,716 patients, only 47% received GCC, with variation by age at diagnosis: 67% of children, 43% of AYAs, and 30% of adults. In multivariable models, patients who received part or all care (

conclusionGCC was associated with improved survival in patients with metastatic osteosarcoma in California. However, we found disparities in the delivery of GCC, highlighting the need for target interventions to improve delivery of GCC in this patient population.

Indexed as

OsteosarcomaAdolescentAdultBone NeoplasmsCaliforniaChildChild, PreschoolFemaleGuideline AdherenceHumansInfantInfant, NewbornMaleMiddle AgedPractice Guidelines as TopicYoung Adult

Identifiers

PMID38381995
PMCPMC11747934
OpenAlexW4392016040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.